The bull case for National Australia Bank Ltd

The perennial under-performer could finally be attracting international fund managers for the first time in 14 years and local investors should be excited about the upcoming divestment of Clydesdale Bank.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

All eyes are now on National Australia Bank Ltd.'s (ASX: NAB) divestment of Clydesdale Bank after it sold its entire stake in Great Western Bank for $1.46 billion.

While the sale of US-based Great Western will force NAB to recognise a $396 million loss, investors are in a pretty forgiving mood and have bid the stock up 1.8% to $34.48 in early trade as experts speculate that the bank's long-term underperformance is about to come to an end.

The loss from the Great Western transaction has been anticipated by the market and the proceeds from the sale will lift the bank's Common Equity Tier-1 ratio by 34 basis points (or 0.34 of a percentage point) to around 10%.

NAB is also readying itself to shed another bothersome asset that has been a big drag on its profitability. I am referring to its UK-based Clydesdale Bank and the Australian Financial Review reports that NAB has two windows of opportunity to undertake the divestment if it wants to meet its self-imposed calendar year-end deadline.

The first is after the earnings onslaught of the August reporting season and the second will be just after it releases its full year result that is expected on October 28.

The big question on the minds of shareholders is what to do with your shares in Clydesdale. The bank will be spun-off as a separately listed entity on the London Stock Exchange, although Clydesdale will have a secondary listing on the ASX as NAB shareholders will be stuck with 70%-80% of the demerged entity.

The UK bank has been so destructive to NAB's shareholder value over the years that I won't be surprised to see many wanting to wash their hands of the investment.

But I believe that would be a mistake. Sure, history has shown that shares in spin-offs typically outperform their parents over a 12 to 24-month period, but I am not primarily focused on this.

I think Clydesdale holds strategic value to local investors in an age where international equity exposure is gaining prominence.

While we have a good handful of ASX-listed stocks with material offshore earnings, we have very few choices of companies that have next to no exposure to the Australian economy. For this reason alone, I think there will be considerable interest in Clydesdale Bank – assuming the price is right.

It's also worth noting that since wealth manager AMP Limited (ASX: AMP) divested its UK fund manager Henderson Group plc (ASX: HGG) in early 2004, the spin-off has surged by over 500% compared with AMP's 29.1% gain. Henderson is also listed in London.

While local investors are casting an eye over to the UK, CLSA believes that offshore fund managers are looking closely at NAB.

These foreign investors have shunned NAB compared with the other big three banks as its operational problems have made NAB "un-investable", according to the investment bank.

NAB

If you looked at earnings per share growth over the past 14 years, NAB only generated 2% growth while its peers have produced a 174% increase to earnings.

But international investors have started buying NAB shares in the last two quarters and their attitude towards the bank may be changing for the first time since 2000.

As I mentioned in my article yesterday, I think NAB represents good value and is a "buy" in my book.

Motley Fool contributor Brendon Lau owns shares of AMP Limited and National Australia Bank Limited. Follow me on Twitter - https://twitter.com/brenlau The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »